QANDLI DIABETNING YURAK-QON TOMIR ASORATLARI VA ULARNI OLDINI OLISHNING ZAMONAVIY USULLARI
Abstract
Ushbu maqolada qandli diabetning yurak-qon tomir asoratlari — yurak ishemik kasalligi, miokard infarkti, insult, yurak yetishmovchiligi, periferik arteriya kasalligi va diabetik kardiomiopatiya — ularning rivojlanish mexanizmlari nuqtai nazaridan tahlil qilingan. Maqolada uzoq davom etuvchi giperglikemiyaning qon tomir endoteliysi, yurak mushagi va vegetativ nerv tizimiga ta'siri, shuningdek oksidlovchi stress va surunkali yallig'lanish jarayonlarining bu asoratlar rivojlanishidagi o'rni yoritilgan. Zamonaviy klinik tadqiqotlar asosida SGLT2 ingibitorlari, GLP-1 retseptor agonistlari, statinlar, arterial bosimni nazorat qilish va turmush tarzini o'zgartirishning kardiovaskulyar xavfni kamaytirishdagi samaradorligi ko'rib chiqilgan. Maqola qandli diabetli bemorlarda yurak-qon tomir asoratlarining oldini olish individual va kompleks yondashuvni talab qilishini asoslaydi hamda amaliy tibbiyot xodimlari uchun dolzarb bo'lgan zamonaviy tavsiyalarni umumlashtiradi.
References
1. American Diabetes Association Professional Practice Committee.“Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024.”Diabetes Care. 2024;47(Suppl 1):S179–S218.
Manba: PubMed / Diabetes Care jurnali.PMID: 38078592.
2. Low Wang CC, Hess CN, Hiatt WR, Goldfine AB.“Clinical Update: Cardiovascular Disease in Diabetes Mellitus.” Circulation Research. 2016;118(11):1808–1829.
Manba: PubMed.DOI: 10.1161/CIRCRESAHA.116.307635.
3. Einarson TR, Acs A, Ludwig C, Panton UH.“Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review.”Cardiovascular Diabetology. 2018;17:83.
4. Zelniker TA, Wiviott SD, Raz I, et al.“SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes.”Lancet. 2019;393(10166):31–39.
5. Davies MJ, Aroda VR, Collins BS, et al.“Management of Hyperglycemia in Type 2 Diabetes, 2022.”Diabetes Care. 2022;45(11):2753–2786.
6. Giacco F, Brownlee M. "Oxidative Stress and Diabetic Complications." Circulation Research. 2010;107(9):1058–1070.Manba: PubMed / Circulation Research jurnali. DOI: 10.1161/CIRCRESAHA.110.223545.
7. Shah AD, Langenberg C, Rapsomaniki E, va boshqalar. "Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people." Lancet Diabetes & Endocrinology. 2015;3(2):105–113.Manba: PubMed.PMID: 25466521. DOI: 10.1016/S2213-8587(14)70219-0.
8. Wong ND, Sattar N. "Cardiovascular Risk in Diabetes Mellitus: Epidemiology, Assessment and Prevention." Nature Reviews Cardiology. 2023;20(10):685–695. Manba: PubMed.PMID: 37193856. DOI: 10.1038/s41569-023-00877-z.
9. Adabiyotlar ro'yxatiga qo'shiladigan qismi (9–14):
Tan Y, Zhang Z, Zheng C, Wintergerst KA, Keller BB, Cai L. "Mechanisms of Diabetic Cardiomyopathy and Potential Therapeutic Strategies: Preclinical and Clinical Evidence." Nature Reviews Cardiology. 2020;17(9):585–607.
Manba: PubMed / Nature Reviews Cardiology jurnali. DOI: 10.1038/s41569-020-0339-2.
10. Zinman B, Wanner C, Lachin JM, va boshqalar. "Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes." New England Journal of Medicine. 2015;373(22):2117–2128.
Manba: PubMed.PMID: 26378978. DOI: 10.1056/NEJMoa1504720.
11. Marso SP, Daniels GH, Brown-Frandsen K, va boshqalar. "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes." New England Journal of Medicine. 2016;375(4):311–322.
Manba: PubMed.PMID: 27295427. DOI: 10.1056/NEJMoa1603827.
12. Cholesterol Treatment Trialists' (CTT) Collaborators. "Efficacy of Cholesterol-Lowering Therapy in 18,686 People with Diabetes in 14 Randomised Trials of Statins: A Meta-Analysis." Lancet. 2008;371(9607):117–125.
Manba: PubMed.PMID: 18191683. DOI: 10.1016/S0140-6736(08)60104-X.
13. ACCORD Study Group. "Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus." New England Journal of Medicine. 2010;362(17):1575–1585.
Manba: PubMed. DOI: 10.1056/NEJMoa1001286.
14. Look AHEAD Research Group. "Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes." New England Journal of Medicine. 2013;369(2):145–154.
Manba: PubMed.PMID: 23796131. DOI: 10.1056/NEJMoa1212914
15. Emerging Risk Factors Collaboration (Sarwar N, Gao P, Kondapally Seshasai SR, va boshqalar). "Diabetes Mellitus, Fasting Blood Glucose Concentration, and Risk of Vascular Disease: A Collaborative Meta-Analysis of 102 Prospective Studies." Lancet. 2010;375(9733):2215–2222.
Manba: PubMed.PMID: 20609967. DOI: 10.1016/S0140-6736(10)60484-9.
16. UK Prospective Diabetes Study (UKPDS) Group. "Effect of Intensive Blood-Glucose Control with Metformin on Complications in Overweight Patients with Type 2 Diabetes (UKPDS 34)." Lancet. 1998;352(9131):854–865.
Manba: PubMed.PMID: 9742977.
17. Vinik AI, Ziegler D. "Diabetic Cardiovascular Autonomic Neuropathy." Circulation. 2007;115(3):387–397.
Manba: PubMed.PMID: 17242296. DOI: 10.1161/CIRCULATIONAHA.106.634949.
18. ASCEND Study Collaborative Group (Bowman L, Mafham M, va boshqalar). "Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus." New England Journal of Medicine. 2018;379(16):1529–1539.
Manba: PubMed.PMID: 30146931. DOI: 10.1056/NEJMoa1804988.
19. Cosentino F, Grant PJ, Aboyans V, va boshqalar. "2019 ESC Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases Developed in Collaboration with the EASD." European Heart Journal. 2020;41(2):255–323.
Manba: PubMed / European Heart Journal jurnali. DOI: 10.1093/eurheartj/ehz486.
